Absci Corp cotiza a 9.09 USD y tiene una capitalización bursátil de $1.6B. En los últimos 12 meses ha facturado $2M con un margen de flujo de caja libre del -3358.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.19 | $-0.23 |
| Estimado | $-0.20 | $-0.20 | $-0.20 | $-0.17 |
| Sorpresa | — | — | +5.0% | -35.3% |
| Métrica | ABSI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -4297.0% | -38.6% | -4258.4% |
| Net Margin | -4113.7% | -33.6% | -4080.1% |
| FCF Margin | -3358.3% | -13.9% | -3344.4% |
| ROE | -60.8% | -40.4% | -20.4% |
| ROA | -53.3% | -32.0% | -21.2% |
| Current Ratio | 6.57 | 2.84 | +3.73 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |